Effect of Acetyl-L-carnitine in Migraine (ALCAR)

Norwegian University of Science and Technology

Status and phase

Completed

Phase 4

Conditions

Migraine

Treatments

Drug: Acetyl-L-carnitine

Study type

Interventional

Funder types

Other

Identifiers

NCT01695317

2012-001624-36

Details and patient eligibility

About

Traditionally, beta blockers have been used for migraine prophylaxis, but in later years also antiepileptic drugs. Contraindications and side effects have to some degree limited their use, and new prophylactics that can be used by most migraine sufferers and with little side effects are in demand. One product that may seem to fulfill these requirements is Acetyl-L-carnitine, which is a dietary supplement and naturally occurs in plants and animals. L-carnitine is necessary for fatty-acid metabolism and energy production.

To our knowledge, no placebo-controlled studies have previously evaluated the efficacy of Acetyl-L-carnitine in adults with migraine.

The aims of the present study is to evaluate the efficacy of Acetyl-L-carnitine as a prophylaxis in migraine patients

Full description

The study will be a single-centre double-blinded, randomized, placebo controlled crossover study with Acetyl-L-carnitine or placebo. We plan to include 72 patients. The follow up duration will be 36 weeks. The study will be performed according to Good Clinical Practice, and relying partly on the International Headache Society Guidelines for controlled trials of drugs in migraine from 2012 and partly on the guidelines divulged by the International Headache Society task force on trial guidelines for chronic migraine.

After a screening visit including a neurological consultation, eligible patients will sign an informed consent declaration before they enter a 4 week run-in (baseline) period when they keep a headache diary. After 4 weeks they return for the second visit. If they have had 2 or more migraine attacks they are allowed to proceed in the study. If they have less than 2 migraine attacks (required for proceeding in the study), they are allowed to extend the baseline period another 4 weeks. Those who then during the whole 8 week period have on average 2 or more migraine attacks per month are also allowed to proceed. Otherwise they are excluded from the study.

Details of the treatment period The duration of each of the two treatment periods is 12 weeks. During each period there will be one telephone contact at the start of each treatment period to remind patients to start with medicines, and one after 2 weeks to check compliance and side effects. In the second last week of every treatment period there will be a doctor and nurse visit with drug accounting and dispensing of new medicines for the next period. At this visit one will ensure that the patient has just enough medicines left to finish the period before the wash-out. As recommended in crossover studies, the participants enter a washout period of 4 weeks between the two treatment periods, to reduce the risk of carryover effect.

Randomization Randomization will be generated using a computerized procedure. A randomization list containing 72 patient numbers is made before the start of the study, and the patient number is then indicated on a package with medicines for that patient. The study has a crossover design, and the two different treatment periods (active or placebo) can arise to two different treatment sequences (AP or PA). Patients are therefore randomized in blocks of 4 where one of these two treatment sequences is assigned to each patient in random order. With 72 patients to be included, this means that 18 patients are randomized in each block. In each block, 50% patients have the treatment sequence AP, and 50% PA in a random order.

Enrollment

72 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 to 65 years
Signed informed consent
Migraine with or without aura according to International Classification of Headache Disorders, second version (ICHD-2) criteria
chronic migraine according to the ICHD-2 criteria (revision 1)
Retrospectively have 2 or more migraine attacks per month during the last 3 month
During the baseline period have 2 or more migraine attacks
Debut of migraine at least one year prior to inclusion
Start of migraine before age 50 years
Body mass index (BMI )between 18-35 kg/m2
No medication overuse during the last 3 months defined as headache >14 days/month combined with overuse simple analgesics >14 days/month or triptans or combined medications ≥ 10 days/month.

Exclusion criteria

Interval headache not distinguishable from migraine
Chronic tension-type headache or other headache than migraine occurring on ≥ 15 days/month with or without medication overuse
Pregnancy, nursing or inability to use contraceptives
Hypersensitivity to active substance
History of angioneurotic edema, diabetes mellitus, significant psychiatric illness and/or Hospital anxiety and Depression Scale( HADS) anxiety score ≥ 11 or HADS depression score ≥ 11, and/or use of selective serotonin reuptake inhibitors (SSRI), antipsychotic medication, or antidepressant medication during the last 3 months
Use of daily migraine prophylactics less than 3 months prior to start of study
Previous use of Acetyl-L-carnitine
BMI <18 kg/m2 or BMI > 35 kg/m2
Having tried ≥ 3 prophylactic drugs against migraine during the last 5 years
Subjects requiring detoxification from acute medication
Patients who consistently fail to respond to any acute migraine medication
Patients with alcohol or illicit drug dependence; 13) Subjects with renal disease or decreased renal function
Previous or present history of asthma or vascular disease, arterial claudication included.